These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 19181644)

  • 1. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.
    Lust JA; Lacy MQ; Zeldenrust SR; Dispenzieri A; Gertz MA; Witzig TE; Kumar S; Hayman SR; Russell SJ; Buadi FK; Geyer SM; Campbell ME; Kyle RA; Rajkumar SV; Greipp PR; Kline MP; Xiong Y; Moon-Tasson LL; Donovan KA
    Mayo Clin Proc; 2009 Feb; 84(2):114-22. PubMed ID: 19181644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma.
    Lust JA; Lacy MQ; Zeldenrust SR; Witzig TE; Moon-Tasson LL; Dinarello CA; Donovan KA
    Am J Hematol; 2016 Jun; 91(6):571-4. PubMed ID: 26945843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease.
    Dinarello CA
    Mayo Clin Proc; 2009 Feb; 84(2):105-7. PubMed ID: 19181642
    [No Abstract]   [Full Text] [Related]  

  • 4. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells.
    Smith MR; Xie T; Joshi I; Schilder RJ
    Br J Haematol; 1998 Sep; 102(4):1090-7. PubMed ID: 9734662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; López Corral L; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Olavarría E; Quintana N; García JL; Bladé J; Lahuerta JJ; San Miguel JF
    N Engl J Med; 2013 Aug; 369(5):438-47. PubMed ID: 23902483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone.
    Puthier D; Bataille R; Barillé S; Mellerin MP; Harousseau JL; Ponzio A; Robillard N; Wijdenes J; Amiot M
    Blood; 1996 Dec; 88(12):4659-66. PubMed ID: 8977259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
    Kuku I; Bayraktar MR; Kaya E; Erkurt MA; Bayraktar N; Cikim K; Aydogdu I
    Mediators Inflamm; 2005 Aug; 2005(3):171-4. PubMed ID: 16106104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of endotoxin and dexamethasone induces type II interleukin 1 receptor (IL-1r II) in monocytes: a comparison to interleukin 1 beta (IL-1 beta) and interleukin 1 receptor antagonist (IL-1ra).
    Brown EA; Dare HA; Marsh CB; Wewers MD
    Cytokine; 1996 Nov; 8(11):828-36. PubMed ID: 9047079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1.
    Xiong Y; Donovan KA; Kline MP; Gornet MK; Moon-Tasson LL; Lacy MQ; Dispenzieri A; Gertz MA; Greipp PR; Lust JA
    J Interferon Cytokine Res; 2006 Feb; 26(2):83-95. PubMed ID: 16487028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
    Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
    N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial.
    Smith CJ; Hulme S; Vail A; Heal C; Parry-Jones AR; Scarth S; Hopkins K; Hoadley M; Allan SM; Rothwell NJ; Hopkins SJ; Tyrrell PJ
    Stroke; 2018 May; 49(5):1210-1216. PubMed ID: 29567761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.
    Bisping G; Kropff M; Wenning D; Dreyer B; Bessonov S; Hilberg F; Roth GJ; Munzert G; Stefanic M; Stelljes M; Scheffold C; Müller-Tidow C; Liebisch P; Lang N; Tchinda J; Serve HL; Mesters RM; Berdel WE; Kienast J
    Blood; 2006 Mar; 107(5):2079-89. PubMed ID: 16278310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients.
    Liou LB
    Clin Exp Rheumatol; 2001; 19(5):515-23. PubMed ID: 11579710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.
    Minarik J; Pika T; Radocha J; Jungova A; Straub J; Jelinek T; Pour L; Pavlicek P; Mistrik M; Brozova L; Krhovska P; Machalkova K; Jindra P; Spicka I; Plonkova H; Stork M; Bacovsky J; Capkova L; Sykora M; Kessler P; Stejskal L; Heindorfer A; Ullrychova J; Skacel T; Maisnar V; Hajek R
    BMC Cancer; 2021 Jan; 21(1):73. PubMed ID: 33451293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and Dexamethasone.
    Tassone P; Forciniti S; Galea E; Savino R; Turco MC; Iacopino P; Tagliaferri P; Morrone G; Ciliberto G; Venuta S
    Cell Death Differ; 2000 Mar; 7(3):327-8. PubMed ID: 10866493
    [No Abstract]   [Full Text] [Related]  

  • 19. Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis.
    Bera S; Greiner S; Choudhury A; Dispenzieri A; Spitz DR; Russell SJ; Goel A
    Neoplasia; 2010 Dec; 12(12):980-92. PubMed ID: 21170263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.